Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Palvella Therapeutics ( (PVLA) ).
On January 12, 2026, Palvella Therapeutics posted a new corporate presentation outlining the advancement of its late‑stage pipeline, led by QTORIN 3.9% rapamycin anhydrous gel, which it positions as a potential first FDA‑approved, first‑line standard‑of‑care therapy for microcystic lymphatic malformations and cutaneous venous malformations, collectively representing more than 100,000 diagnosed U.S. patients and an estimated $1‑$3 billion‑plus U.S. peak sales opportunity. The company highlighted that 2025 milestones, including positive Phase 2 data in cutaneous venous malformations in December 2025 and full enrollment of the Phase 3 SELVA trial in microcystic lymphatic malformations, have set up a catalyst‑rich 2026, with topline Phase 3 data in March 2026, a targeted U.S. approval in 2027, new QTORIN rapamycin and QTORIN pitavastatin programs, and multiple planned Phase 2 and Phase 3 trials supporting its longer‑term vision of building an enduring rare disease franchise with 10 or more first‑in‑disease therapies in late‑stage development or on the market.
The most recent analyst rating on (PVLA) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.
Spark’s Take on PVLA Stock
According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.
The score is held down primarily by weak financial performance (no revenue in 2023–2024, ongoing losses, and persistent cash burn), partially offset by strong technical uptrend signals and positive recent corporate milestones (notably Phase 2 efficacy results and stated cash runway). Valuation remains pressured due to negative earnings.
To see Spark’s full report on PVLA stock, click here.
More about Palvella Therapeutics
Palvella Therapeutics, Inc. is a rare disease biopharmaceutical company focused on developing and commercializing first-in-disease therapies for serious, rare skin diseases and vascular malformations. Leveraging its proprietary QTORIN topical platform and an “innovative capital efficient business model,” the company is targeting previously untreated orphan indications such as microcystic lymphatic malformations, cutaneous venous malformations, clinically significant angiokeratomas and disseminated superficial actinic porokeratosis, aiming to unlock multi‑billion‑dollar market opportunities in these high‑unmet‑need niches.
Average Trading Volume: 249,648
Technical Sentiment Signal: Buy
Current Market Cap: $1.15B
See more insights into PVLA stock on TipRanks’ Stock Analysis page.